C
lostridium difficile is a Gram-positive, sporogenic, anaerobic bacterium that is the most common cause of antibiotic-associated diarrhea within health care systems of the developed world (24, 34) . Perturbation of the hosts' indigenous microbiota by broad-spectrum antibiotic treatment, such as clindamycin, is a major risk factor for C. difficile colonization, disease, and transmission (4, 10) . C. difficile colonization is associated with a spectrum of outcomes ranging from asymptomatic carriage, chronic diarrhea, and pseudomembranous colitis to multiple-organ dysfunction syndrome (6, 17) . The first-line antibiotic treatment for C. difficile disease is vancomycin or metronidazole (39) ; however, recurrent disease (relapse with the same strain or reinfection with a different strain) occurs in ϳ15 to 35% of patients (1) . Recurrence and transmission are relatively poorly understood aspects of C. difficile biology that likely underpin its persistence within health care systems.
During the past decade, distinct genetic clades of C. difficile have emerged that are responsible for epidemics within North America and Europe and continue to disseminate globally (18, 19) . Among the most notable of these clades is the so-called "hypervirulent" variant of C. difficile, commonly genotyped as PCR ribotype 027 or North American pulsotype 1, which is associated with high rates of mortality and disease recurrence, as well as severe hospital outbreaks (7, 12, 36, 37) . In addition, other genetic variants, such as C. difficile PCR ribotype 012, continue to be endemic in health care systems (2) .
Sporulation, the production of metabolically dormant endospores from vegetative cells, is a property of several bacterial groups, including Clostridium and Bacillus (25, 38) . In Bacillus, Spo0A is a key transcriptional regulator that is required in the early stages of sporulation (23) . Orthologues of Spo0A are encoded by different members of the genera Clostridium and Bacillus, and genetic inactivation results in a sporulation-null phenotype in all species studied to date (9, 25, 28, 35) . C. difficile produces highly infective endospores that are excreted by infected patients, allowing the oxygen-sensitive pathogen to retain viability outside the host (22) . Spores of C. difficile can also resist commonly used disinfectant regimens and, as a result, are able to persist in the environment, generating a potential transmission reservoir that confounds standard infection control measures (5, 11, 20) .
C. difficile is unusual among some spore-forming pathogens, including other clostridia, in being highly transmissible between humans. In contrast, there is little evidence of person-to-person transmission of Clostridium botulinum (32) , Clostridium tetani (8), or Bacillus anthracis (30) . Thus, transmissibility may be key to the continued survival and persistence of C. difficile in the human population, and it suggests that the pathogen is highly adapted to its niche. Here, we use a murine model of C. difficile infection to investigate the role of the spo0A gene in distinct PCR ribotypes 027 and 012 during infection and transmission.
MATERIALS AND METHODS
C. difficile strains and culture. All C. difficile strains were grown for 24 to 48 h at 37°C under anaerobic conditions in a MACS MG-500 anaerobic workstation (Don Whitley Scientific, West Yorkshire, United Kingdom). C. difficile was routinely cultured in Wilson's broth with agitation (80 rpm) or on brain heart infusion (BHI) (Sigma, United Kingdom) agar plates with appropriate antibiotic selection unless otherwise stated. Escherichia coli strains were grown at 37°C using Luria-Bertani (LB) broth or agar with appropriate antibiotic selection. Table 1 describes the strains used in this study.
C. difficile was enumerated from fresh feces as previously described (21). Briefly, samples (100 mg feces/ml phosphate-buffered saline [PBS]) were serially diluted in PBS and plated on CCEY agar (Bioconnections, Whetherby, United Kingdom) supplemented with 0.1% taurocholate (Sigma, United Kingdom). This was done within 30 min of excretion. For the enumeration of spores, samples were mixed with 100% ethanol (1:1 ratio) for 1 h at room temperature to kill vegetative cells, pelleted, washed in PBS, and cultured as described above.
Mutagenesis and genetic complementation. ClosTron technology was used to make targeted mutants in the spo0A gene of C. difficile strains R20291 (PCR ribotype 027) and 630 (PCR ribotype 012), as previously described (13, 14) . Briefly, the group II Ll.LtrB intron was retargeted to spo0A by SOE PCR as previously described (13, 14) . The retargeted intron, an antisense insertion between nucleotides 178 and 179, was then cloned into the HindIII and BsrGI sites of pMTL007 (C. difficile 630) or pMTL007C-E2 (C. difficile R20291) and transformed into the E. coli conjugation donor strain CA434. C. difficile strains 630 and R20291 were mated with the E. coli donor harboring the retargeted pMTL007 or pMTL007C-E2, respectively, as previously described (26) . Transconjugants were selected for in the presence of thiamphenicol (15 g/ml; Sigma-Aldrich, Dorset, United Kingdom). For pMTL007, mobilization of the intron to the spo0A gene of C. difficile 630 was induced using isopropyl-␤-D-thiogalactopyranoside (IPTG) as previously described (14) . pMTL007C-E2 is a version of pMTL007 in which the promoter of the group II intron is modified for a constitutive fdx promoter (13) and as such does not require IPTG induction to direct intron expression to the spo0A gene of C. difficile R20291. Potential transconjugants were then serially diluted onto plates containing lincomycin (15 g/ml; C. difficile R20291; Sigma-Aldrich, Dorset, United Kingdom) or erythromycin (5 g/ml; C. difficile 630; Sigma-Aldrich, Dorset, United Kingdom) to select for chromosomal insertion of the intron. Replica plating with lincomycin (15 g/ml) or erythromycin (5 g/ml) and thiamphenicol (15 g/ml) was performed to select for the restored ermB retrotransposition-activated marker (RAM) that signals integration into the genome and loss of the catP gene encoding thiamphenicol resistance carried on the plasmid. Mutants were screened by PCR (see Table S1 in the supplemental material), sequencing, or Southern blot analysis to confirm the chromosomal integration of the intron within the desired genes and loss of plasmids pMTL007 and pMTL007C-E2.
To complement the spo0A mutants, the C. difficile-E. coli shuttle vector pRPF101 was constructed using the ColE1 replicon from pBlueScript II SK(ϩ) (Agilent Technologies, Cheshire, United Kingdom), catP from pJIR418 (31), the C. difficile pCD6 replicon (26) , and oriT from pJB665 (3). The wild-type C. difficile 630 spo0A gene and upstream promoter region were amplified using the oligonucleotide pair spo0A_A1F and spo0A_A2Rb (see Table S1 in the supplemental material), which were designed to enable cleavage with SalI, and cloned into pRPF101, yielding pspo0A. Since the amino acid sequences of Spo0A in both C. difficile R20291 and 630 are identical, only one plasmid was constructed for the complementation of both strains. pspo0A was initially transformed into E. coli CA434, followed by conjugation into the spo0A mutant derivatives as previously described (26) , generating strains R20291⌬spo0A(pspo0A) and 630⌬spo0A(pspo0A), respectively. Thiamphenicol (15 g/ml) was used to select for the pspo0A-containing cells, and cycloserine (250 g/ml; Bioconnections, Whetherby, United Kingdom) and cefoxitin (8 g/ml; Bioconnections, Whetherby, United Kingdom) were used to counterselect for E. coli CA434. Plasmid transfer was verified by pspo0A isolation and restriction analysis (data not shown).
Mouse infections. All experiments were carried out using 5-to 9-week-old specific-pathogen-free mice from colonies maintained at the Wellcome Trust Sanger Institute. Wild-type mice of C57BL/6 genetic background were pretreated with drinking water containing clindamycin (250 mg/liter; Apollo Scientific, Cheshire, United Kingdom) for 7 days. Clindamycin was then withdrawn for 24 h, and donors were infected via oral gavage or transmission, as indicated. When infected via oral gavage, mice received 10 7 vegetative cells and 10 5 spores (R20291 and 630 parental strains) or 10 7 vegetative cells (R20291⌬spo0A and 630⌬spo0A mutant derivatives). For relapsing infection experiments, mice received drinking water containing vancomycin hydrochloride (400 mg/liter; Sigma-Aldrich, Dorset, United Kingdom) for 7 to 10 days. The mice were housed in sterile cages with ad libitum access to food and water. All procedures and mouse handling were performed aseptically in a biosafety cabinet to contain spore-mediated transmission.
A clinical scoring system was employed to track the condition of the mice. Symptoms, including abnormal/hunched gait, piloerection, lethargy, and emaciation, were monitored. Moribund mice or mice displaying overt signs of disease were sacrificed. For pathological analysis, cecum tissue (0.5-cm tubular sections) was carefully excised, opened, and processed for hematoxylin and eosin staining, as previously described (21) . All animal infections were performed in accordance with the United Kingdom Home Office Animals (Scientific Procedures) Act of 1986.
Competitive-index infections. Wild-type C57BL/6 mice (n ϭ 5) were infected via oral gavage with 10 7 CFU in 0.2 ml PBS containing equal proportions of the C. difficile parental strain and the respective isogenic spo0A mutant. In order to determine the inoculum dose and ratio of pRPF101 containing the 825-bp spo0A coding region (and upstream promoter) This study parent to spo0A mutant, the inocula were grown on both CCEY plates (as a nonselective medium) and CCEY plates supplemented with 20 mg/ml lincomycin (which selects for the ermB gene inserted into the spo0A genes of both mutant derivatives). Fecal samples were then diluted as described above and plated on CCEY agar and CCEY agar supplemented with lincomycin, and the competitive index (CI) was determined by dividing the ratio of mutant to parent bacteria using the following formula: CI ϭ (spo0A mutant/parental strain) output /(spo0A mutant/parental strain) input .
The Mann-Whitney test was applied to the log 10 values of the CI ratios to determine the statistical significance of the results. Transmission experiments. Wild-type C57BL/6 donor mice (n ϭ 5) were infected via oral gavage (10 7 CFU in 0.2 ml PBS). To measure transmission efficiency, naïve wild-type C57BL/6 recipient mice (n ϭ 5) were pretreated with clindamycin as described above and used in one of four types of transmission assays as described in Table 2 and Fig. S1 in the supplemental material. Following transmission, recipient mice were individually housed, and the transmission efficiency was determined after 4 days by the isolation of the same strain of C. difficile in the feces that was used to infect the respective donor mice.
TcdA and TcdB quantification. C. difficile cultures were growth in Wilson's broth with shaking for 30 h and pelleted by centrifugation, and the supernatant was removed for TcdA and TcdB quantification. Total and spore counts were determined to ensure equal numbers of vegetative cells in the cultures. For TcdA quantification, microtiter plates were coated with capture antibody by adding 50 l/well of a 2-g/ml solution of anti-TcdA (tgcBiomics GmbH, Mainz, Germany) in PBS and incubating overnight at 4°C. The plates were then washed 3 times in 0.05% Tween20 in PBS (PBS-T) and blocked with 200 l 1% bovine serum albumin (BSA) in PBS for 2 h at room temperature. Purified TcdA (tgcBiomics GmbH, Mainz, Germany) was diluted in 1% BSA-PBS (50 l/well) and used to construct a standard curve. Culture filtrates (50 l/ well) were diluted as described above in order to generate readings within the linear range of the standard curve. Plates were then incubated at room temperature for 2 h, followed by washing in PBS-T as described above. The detection antibody (rabbit anti-Clostridium difficile TcdA; Antibodies-Online GmbH, Aachen, Germany) was diluted 1:5,000 in 1% BSA-PBS, added to the wells (50 l/well), and incubated for 2 h at room temperature. After washing, polyclonal swine anti-rabbit IgG conjugated to horseradish peroxidase (HRP) (Dako, Cambridgeshire, United Kingdom) was diluted 1:1,000 in 1% BSA-PBS, added to the wells (50 l/well), and incubated for 2 h at room temperature. Finally, the plates were washed, and 100 l 3,3=,5,5=-tetramethylbenzidine (TMB) (Sigma-Aldrich, Dorset, United Kingdom) substrate was added for 30 min at room temperature in the dark; 50 l 0.5 M H 2 SO 4 was added to stop the reaction.
TcdB quantification was determined using a TcdB-specific enzymelinked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (tgcBiomics GmbH, Mainz, Germany). Briefly, microtiter plates precoated with anti-TcdB capture antibody were coincubated with either C. difficile culture filtrates or purified TcdB (as described above) and anti-C. difficile TcdB-HRP and incubated for 1 h at 37°C. The plates were then washed, and 100 l TMB substrate was added for 30 min at room temperature in the dark. The reaction was stopped with 50 l 0.5 M H 2 SO 4 . The absorbances of all plates were measured at 450 nm on a FluoStar Omega (BMG Labtech, Bucks, United Kingdom). Data for TcdA and TcdB are from 3 independent experiments performed in triplicate.
Indirect immunofluorescence of C. difficile vegetative cells and spores. Cultures were washed in PBS and seeded onto microscope slides. Briefly, the slides were then fixed in acetone and blocked with 1% BSA in PBS. The wells were incubated with polyclonal rabbit sera (raised against pure wild-type C. difficile 630 spores) and polyclonal mouse sera (raised against 630⌬spo0A vegetative cells), washed in PBS, and reacted with Cy3-conjugated goat anti-rabbit IgG and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (each 1:1,000) in a humidified chamber in the dark. The slides were then mounted in ProLong Gold with DAPI (4=,6-diamidino-2-phenylindole) (Invitrogen, Paisley, United Kingdom) and sealed, and immunofluorescence was assessed using an LSM510 Meta confocal microscope (Carl Zeiss Ltd., Herts, United Kingdom).
Antibodies were generated via subcutaneous delivery of C. difficile 630⌬spo0A into C57BL/6 mice (for anti-vegetative-cell sera; n ϭ 5) or C. difficile 630 pure spores into rabbits (for anti-spore sera; n ϭ 2). Briefly, the animals received 100 l of an ϳ10 8 -CFU/ml culture in each flank, followed by a series of boost immunizations and test bleeds. Sera were collected and stored at 4°C.
RESULTS
C. difficile spo0A is essential for spore formation. We had previously sequenced and fully annotated the complete genomes of representative C. difficile ribotypes 027 (strain R20291) (33) and 012 (strain 630) (29) . C. difficile R20291 and 630 both produce ϳ10 5 spores/ml after 48 h of growth in Wilson's broth, representing Ͻ1% of the total bacterial cells (Fig. 1A) . To evaluate the impact of spo0A on growth and sporulation, defined insertional mutations were generated in the spo0A genes of either C. difficile R20291 or C. difficile 630, yielding mutant derivatives R20291⌬spo0A and 630⌬spo0A, respectively. The vegetative cells of both R20291⌬spo0A and 630⌬spo0A were morphologically indistinguishable from the respective parent strains when examined by light microscopy and displayed similar growth kinetics (data not shown). Both C. difficile spo0A mutant derivatives failed to produce any detectable spores or spore-like elements (15, 35) , as determined by anaerobic culturing after ethanol shock (spores are resistant to ethanol) and indirect immunofluorescence using spore-specific antisera (Fig. 1) .
To demonstrate that the asporogenous phenotype was directly attributable to the spo0A mutation, we complemented the mutated genes using the plasmid pspo0A harboring the wild-type spo0A gene under the control of its native promoter. We found that the complemented spo0A mutants produced spores at levels comparable to those of the parent (P Ͼ 0.05) and were morphologically indistinguishable (Fig. 1) . Collectively, these observations indicate that the spo0A mutation is nonpolar and that expression of the spo0A gene is critical for vegetative cells to differentiate into spores in both C. difficile R20291 and 630.
C. difficile spo0A mutant derivatives cause acute disease in mice. We previously described a C. difficile infection model in mice that mimics many aspects of C. difficile disease, persistence, and transmission in humans (20) (21) (22) . In order to investigate the role of the spo0A gene during the acute phase of C. difficile infection (days 2 to 4 postinfection), we pretreated mice with clindamycin and subsequently infected them with C. difficile R20291, C. difficile 630, or their equivalent spo0A mutant derivatives. Groups of mice infected orally with C. difficile 630 or 630⌬spo0A did not exhibit any overt signs of disease and had a 100% survival rate ( Fig. 2A) . In contrast, mice infected with C. difficile R20291 demonstrated notable signs of disease, such as hunched posture and ruffled fur; however, these clinical symptoms resolved by day 5 postinfection, and all the mice survived. Mice infected with C. difficile R20291⌬spo0A also displayed signs of overt disease, but this was more exaggerated than in R20291-infected mice, with the mice displaying hunched posture, piloerection, lethargy, dehydration, and emaciation. By day 5 postinfection, 80% of R20291⌬spo0A-infected mice were considered to be moribund according to a clinical scoring system and were consequently sacrificed. The remaining 20% resolved the disease and survived. In order to identify any increased pathology associated with R20291⌬spo0A infection, we performed histologic analyses on the ceca of mice infected with C. difficile R20291 or R20291⌬spo0A at day 2 postinfection (Fig. 2B) . At this time point, the mice shed equivalent levels (ϳ10 8 CFU/gram fresh feces) of vegetative C. difficile R20291 or R20291⌬spo0A. Mice infected with C. difficile R20291 also shed spores (ϳ10 6 CFU/gram fresh feces), in contrast to R20291⌬spo0A-infected mice, which did not shed spores. Uninfected clindamycin control mice did not exhibit any pathology. Conversely, at day 2 postinfection, mucosal damage was evident in R20291-and R20291⌬spo0A-infected mice, which included edema and immune cell infiltrate within the cecal mucosa. These observations, however, were much more notable in mice infected with R20291⌬spo0A, which exhibited more pronounced edema, epithelial surface damage, and acute infiltration. Putative pseudomembranes were also visible on the epithelial surface in R20291⌬spo0A-infected mice. The increased virulence exhibited by C. difficile R20291⌬spo0A was not anticipated. We hypothesized that these observations might be related to increased toxin production. We therefore compared the levels of the major toxins TcdA and TcdB from broth grown cultures of wild-type C. difficile R20291 and R20291⌬spo0A using highly sensitive anti-TcdA-and anti-TcdBspecific ELISAs. Low-levels of TcdA and TcdB were detected during mid-exponential-phase growth in both R20291 and R20291⌬spo0A (data not shown). However, during stationary growth (30 h), significantly higher levels both of TcdA (P ϭ 0.0006) and TcdB (P ϭ 0.0005) were detected in C. difficile R20291⌬spo0A than in R20291 cultures (Fig. 2C) . Complementation of the spo0A gene in R20291⌬spo0A reduced the levels of toxins produced, although both TcdA and TcdB were still slightly elevated compared to that produced by wild-type C. difficile R20291 (P ϭϽ0.05).
Therefore, we demonstrated that R20291 and R20291⌬spo0A are virulent in mice and that exaggerated virulence by R20291⌬spo0A during the acute phase of infection is associated with increased TcdA and TcdB production.
The C. difficile spo0A gene is required for persistent, relapsing infection in mice. We previously demonstrated that C. difficile isolated from infected hospital patients can asymptomatically persist in mice for several months (21) . Therefore, we next assessed the contribution of the C. difficile spo0A gene to colonization and persistent infection. To assess this phenotype, CI experiments were performed in which groups of mice were infected with a mixture of equal numbers of parental strain C. difficile and the respective ⌬spo0A mutant, enabling direct fitness comparisons in vivo. In the R20291 background, the ⌬spo0A mutant was recovered at a significantly reduced level compared to wild-type R20291 (Fig. 3A) . We observed that genetic disruption of spo0A resulted in reduced fitness by day 2 postinfection and continued to day 15 postinfection. Although C. difficile 630 does not cause a long-term persistent infection in our murine model, we found that the C. difficile 630⌬spo0A mutant was reproducibly cleared ϳ6 days earlier than its parental strain (data not shown). Additionally, the difference in relative fitness for the 630⌬spo0A mutant was statistically significant by day 5 postinfection (Fig. 3B) . These results indicate that the spo0A gene of C. difficile contributes to intestinal colonization and persistent infection in mice.
Recurrent infection after cessation of antibiotic therapy is a hallmark feature of C. difficile persistence. Given that C. difficile spo0A may affect persistence, we were interested in whether Spo0A also influences relapsing infection. To test this, mice infected with R20291, R20291⌬spo0A, C. difficile 630, or 630⌬spo0A were treated with a 7-day course of oral vancomycin. During this period, the cages were regularly changed to reduce the potential for environmental transmission. We found that vancomycin therapy rapidly decreased the levels of fecal shedding of C. difficile to below the detection limit in all infected groups of mice ( Fig. 4A and B) , as expected, since these strains are sensitive to vancomycin. However, 3 days after vancomycin withdrawal, the mice infected with parental C. difficile R20291 or C. difficile 630 exhibited recurrent infection with the same isolate (i.e., relapse). With C. difficile 630, this relapsing phenotype was observed after the first two courses of vancomycin; however, after a third treatment, the relapse did not occur (Fig. 4B) . In contrast, C. difficile R20291-infected mice consistently relapsed on cessation of treatment for up to 100 days (Fig. 4A) . Significantly, mice infected with either C. difficile R20291⌬spo0A or 630⌬spo0A cleared the infection during the first course of vancomycin and did not demonstrate relapse at any point during the 100-day monitoring period (Fig. 4A and B) .
We hypothesized that recurrence in R20291-and 630-infected mice could be the result of either persistence of the bacterium within the host during vancomycin therapy or recolonization from environmental spores. To address this, mice infected with C. difficile R20291 or C. difficile 630 were treated with a 5-day course of vancomycin, after which the entire intestinal tract (small and large intestine and cecum) was removed and cultured for C. difficile. We consistently failed to detect any C. difficile in the intestinal tracts of mice receiving vancomycin therapy (data not shown). However, we could readily culture C. difficile from mouse chow, cage shavings, and bedding, as well as the fur, mouth, and feet of mice receiving vancomycin treatment, even though cages were changed during the vancomycin treatment. Spores were detected in all locations, indicating that Spo0A acts as a persistence factor, enabling C. difficile to remain in the environment generating an infection reservoir on cessation of antibiotic therapy.
C. difficile spo0A is required for efficient host-to-host transmission. We previously used the murine infection model to demonstrate host-to-host transmission and the highly transmissible nature of various C. difficile ribotypes (20) (21) (22) . Here, we used this model to investigate the role of the C. difficile spo0A gene in host transmission via distinct transmission routes ( Table 2 ; see Fig. S1 in the supplemental material). During transmission experiments, the donor mice shed equivalent levels (ϳ10 8 CFU/gram fresh feces) of vegetative C. difficile R20291, 630, or their respective spo0A mutant derivatives (Fig. 5A ). Mice infected with C. difficile R20291 or C. difficile 630 also shed spores (ϳ10 6 CFU/gram fresh feces), in contrast to mice infected with the spo0A mutants, where spores were undetectable (Fig. 5A) .
Mingling donor mice that were shedding high levels of C. difficile R20291 or 630 with naïve recipient mice for 1 h (in cages without bedding) resulted in 100% transmission (Fig. 5B )(n ϭ 10 for each strain). In contrast, mingling donors excreting C. difficile R20291⌬spo0A or 630⌬spo0A with naïve recipient mice resulted in only 40% or 20% transmission efficiency, respectively. In these experiments, coprophagy was regularly observed, and this behavior likely promotes C. difficile transmission. To further define the transmission route, we placed a porous wall between donor and recipient mice so that the mice could come into contact but coprophagy was blocked. During these experiments C. difficile R20291 and 630 were still transmitted at 100% efficiency, whereas the ⌬spo0A derivatives failed to transmit at a detectable level (Fig.  5B, contact transmission) . Next, we tested transmission between donor and recipient mice that were separated by a double porous wall that prevented coprophagy and direct contact but would still allow airborne transmission. In these experiments, C. difficile R20291 and 630 were transmitted at 60% efficiency, whereas the respective ⌬spo0A derivatives failed to transmit (Fig. 5B, airborne  transmission) . Thus, Spo0A plays a key role in the transmission of C. difficile between hosts sharing a contained environment but with no direct contact.
Environmental C. difficile spores are proposed to be a significant transmission reservoir (20, 27) . To mimic this situation, we contaminated cages (without bedding) by placing donor mice shedding C. difficile in cages for 1 h and then removed the feces and allowed the cages to stand overnight (ϳ16 h) in a sterile environment so that only the aerobic-resistant spores survived. Exposure of naïve recipient mice to the environment contaminated with C. difficile R20291 or 630 spores resulted in 100% transmission to naïve recipient mice. In contrast, none of the naïve recipient mice exposed to C. difficile R20291⌬spo0A-or 630⌬spo0A-contaminated cages became colonized (Fig. 5B) .
DISCUSSION
The availability of a murine infection model opens the way to study the genetic basis of C. difficile disease, relapse, persistence, and transmission. Here, we demonstrated for the first time that the spo0A gene of clinically relevant genetic variants of C. difficile is essential for persistent infection and efficient host-to-host transmission. Importantly, we also showed that a functional spo0A gene is required for relapsing infection after vancomycin therapy, and we further illustrated that the local environment (i.e., cage, food, mouse fur, etc.) may serve as a reservoir of C. difficile. Despite difficile 630, R20291, 630⌬spo0A, and R20291⌬spo0A, demonstrating the percentages of naïve recipient mice that acquired infection following exposure to infected donor mice via mingling, contact, airborne, or environmental transmission. The efficiency of transmission was determined as described in Materials and Methods. multiple attempts, we could not culture C. difficile from the intestinal tracts of challenged mice during vancomycin treatment, indicating that maintenance of C. difficile within the intestinal tract was not a likely cause of relapse, although we cannot rule out the possibility that C. difficile persisted at very low levels or in a nonculturable form. We could, however, readily culture C. difficile from inside the cage during treatment. Given the highly transmissible nature of environmental spores, it is possible that relapsing infection was in fact reinfection with the same strain that contaminated the local environment before antibiotic treatment and persisted until after antibiotic therapy ended. The inability of C. difficile spo0A mutants to cause relapsing infection and form spores is consistent with this model. Indeed, antibiotic treatment of mice perturbs the intestinal microbiota and makes them extremely susceptible to C. difficile infection via environmental spores (21) .
As expected, genetic inactivation of spo0A resulted in an asporogenous phenotype in C. difficile R20291 (ribotype 027) and 630 (ribotype 012) (35) . In addition to not being able to form spores, we demonstrated that C. difficile spo0A mutants produced elevated levels of the toxins TcdA and TcdB in vitro compared to the respective wild-type parental strains. Therefore, Spo0A may negatively regulate toxin production, which was associated with increased virulence for mice for the C. difficile 027 variant. This finding was in contrast to the observations of Underwood et al. (35) , which indicated that a C. difficile 630 spo0A mutant produced Ͻ10% of the parental levels of TcdA (35) . This discrepancy may reflect the different methods used to quantify toxin levels. In the well-characterized model organism Bacillus subtilis, Spo0A regulates processes other than spore formation, such as efflux pumps and metabolism (23) . Consequently, it is possible that, in addition to spore formation, there are other functions controlled by Spo0A that may play a role in persistence and transmission. Future experiments that define the C. difficile Spo0A regulon at the transcriptional and proteomic levels should identify persistence and transmission factors controlled by Spo0A in C. difficile.
